Abstract
Provided here are arylpiperazine pharmacophore compositions that mitigate levodopa-induced dyskinesia and significantly improve Parkinson’s disease-like symptoms. These dopamine D3 receptor ligands have high affinity and selectivity, are orally active, and have desirable drug-like properties.
Application number
17840563
Date of Application
6/14/2022.
Inventor
Marcel Daadi